Etripamil Nasal Spray: Therapeutic Potential for Treating Paroxysmal Supraventricular Tachycardia.

Jessica Huston, Ariana Genovese, Andrea Ashchi, Amanda DeLuca, Jordyn Wiener, Elias Deeb, Alexander Deeb, Rebecca F Goldfaden

American journal of cardiovascular drugs : drugs, devices, and other interventions 2023 Sep

filter terms:

Patients with arrythmias are at an increased risk of heart-related comorbidities and complications. Specifically, patients with paroxysmal supraventricular tachycardia (PSVT), a type of arrythmia, are at increased risk of lightheadedness or shortness of breath, due to the increased rate of the heartbeat. Most patients are prescribed oral medications to control their heart rates and maintain a normal heart rhythm. Researchers have been tasked with discovering alternative treatment options with new delivery methods to treat arrythmias such as PSVT. A nasal spray was subsequently designed and is currently undergoing clinical studies. This review aims to present and discuss the current clinical and scientific evidence pertaining to etripamil. © 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Citation

Jessica Huston, Ariana Genovese, Andrea Ashchi, Amanda DeLuca, Jordyn Wiener, Elias Deeb, Alexander Deeb, Rebecca F Goldfaden. Etripamil Nasal Spray: Therapeutic Potential for Treating Paroxysmal Supraventricular Tachycardia. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2023 Sep;23(5):471-475